4.4 Review

Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin

Journal

CURRENT OPINION IN PHARMACOLOGY
Volume 9, Issue 4, Pages 434-444

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2009.06.012

Keywords

-

Funding

  1. Alzheimer's Associations
  2. National Institutes of Health [AG18379, AG18884]

Ask authors/readers for more resources

Alzheimer's disease (AD) is a neurodegenerative disorder of the elderly. Deposition of amyloid beta plaque and associated neuroinflammation are the major hallmarks of AD. Whereas reactive oxygen species (ROS) and activated microglial cells contribute to neuronal loss, nuclear factor kappa B and apolipoprotein E participate in inflammatory process of AD. Current FDA approved drugs provide only symptomatic relief in AD. For broad spectrum of activity, some natural products are also being tested. Turmeric is used as an anti-inflammatory medicine in various regions of Asia. Curcumin, which is a yellow colored polyphenol compound present in turmeric, showed anti-inflammatory properties. Herein, we discuss the neurobiological and neuroinflammatory pathways of AD, evaluate different molecular targets and potential therapeutic agents, including curcumin, for the treatment of AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available